| Autor: |
Andrea L. Cathcart, Colin Havenar-Daughton, Florian A. Lempp, Daphne Ma, Michael A. Schmid, Maria L. Agostini, Barbara Guarino, Julia Di iulio, Laura E. Rosen, Heather Tucker, Joshua Dillen, Sambhavi Subramanian, Barbara Sloan, Siro Bianchi, Dora Pinto, Christian Saliba, Katja Culap, Jason A Wojcechowskyj, Julia Noack, Jiayi Zhou, Hannah Kaiser, Sooyoung Lee, Nisar Farhat, Arthur Chase, Martin Montiel-Ruiz, Exequiel Dellota, Arnold Park, Roberto Spreafico, Anna Sahakyan, Elvin J. Lauron, Nadine Czudnochowski, Elisabetta Cameroni, Sarah Ledoux, Yoshihiro Kawaoka, Adam Werts, Christophe Colas, Leah Soriaga, Amalio Telenti, Lisa A. Purcell, Seungmin Hwang, Gyorgy Snell, Herbert W. Virgin, Davide Corti, Christy M. Hebner |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 and VIR-7832 were derived from a parent antibody (S309) isolated from memory B cells of a 2003 severe acute respiratory syndrome coronavirus (SARS-CoV) survivor. Both mAbs contain an “LS” mutation in the Fc region to prolong serum half-life and potentially enhance distribution to the respiratory mucosa. In addition, VIR-7832 encodes an Fc GAALIE mutation that has been shown previously to evoke CD8+ T-cells in the context of an in vivo viral respiratory infection. VIR-7831 and VIR-7832 potently neutralize wild-type and variant authentic virus in vitro as well as variant pseudotyped viruses. In addition, they retain activity against monoclonal antibody resistance mutations conferring reduced susceptibility to currently authorized mAbs. The VIR-7831/VIR-7832 epitope does not overlap with mutational sites in current variants of concern and continues to be highly conserved among circulating sequences consistent with the high barrier to resistance observed in vitro. Furthermore, both mAbs can recruit effector mechanisms in vitro that may contribute to clinical efficacy via elimination of infected host cells. In vitro studies with these mAbs demonstrated no enhancement of infection. In a Syrian Golden hamster proof-of concept wildtype SARS-CoV-2 infection model, animals treated with VIR-7831 had less weight loss, and significantly decreased total viral load and infectious virus levels in the lung compared to a control mAb. Taken together, these data indicate that VIR-7831 and VIR-7832 are promising new agents in the fight against COVID-19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
